To propose a prospective therapeutic target for the treatment of docetaxel-resistant breast cancer, this work described a pathway of acquired docetaxel resistance in these cells, presumably involving direct interactions with BCL-2 and CCND1. Here, CCND1 is linked to breast cancer.